Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target

Patent metadata

Field	Value
Publication number	US-2016257953-A1
Application number	US-201615069258-A
Country	US
Kind code	A1
Filing date	Mar 14, 2016
Priority date	Oct 6, 2004
Publication date	Sep 8, 2016
Grant date	—

Abstract

The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.

First claim

What is claimed is:

1 . A method of inhibiting expression of B7-H1 in a tumor cell or a tumor-infiltrating leukocyte, the method comprising: (a) identifying a subject with cancer, the cancer comprising a target cell that expresses B7-H1, the target cell being a tumor cell or a tumor-infiltrating leukocyte; and (b) introducing into the target cell: (i) an antisense oligonucleotide that hybridizes to a B7-H1 transcript, wherein the antisense oligonucleotide inhibits expression of B7-H1 in the cell; or (ii) a B7-H1 interference RNA (RNAi).

Assignees

• Mayo Foundation

Inventors

• Chen Lieping
• Strome Scott E
• Kwon Eugene D

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57525

  of the liver or pancreas · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title